Latest Tumor markers Stories

New market research report “Tumor Markers: Innovative Technologies and Emerging Business Opportunities” worked out by Venture Planning Group (VPG) has been recently published by Market Publishers Ltd. According to the study, further development of the tumor marker market will be spurred by the technological advancements in tumor diagnostics and treatment and introduction of new antigens. London, UK (PRWEB) December 24, 2012 Tumor markers form one of the most important segments of the...

NEW YORK, Dec. 14, 2012 /PRNewswire/ -- Despite the volume of prostate cancer tests and treatments, experts and their patients are continually challenged to predict the disease's course and apply the most appropriate treatment. Now, two new diagnostic innovations - the PCA3 urine test and a more targeted prostate biopsy technique - could refine the way doctors diagnose prostate cancer and, subsequently, the way patients elect to treat it. (Photo:...

NEW YORK, Dec. 5, 2012 /PRNewswire/ -- This spring, the U.S. Preventative Services Task Force (USPSTF) gave men a free pass on their annual prostate-specific antigen (PSA) blood test. Many prostate cancer treatment experts, including robotic surgeon, Dr. David Samadi, worry that pass could cost some men their lives. In the November Health Radar newsletter published by NewsmaxHealth, Dr. Samadi called the USPSTF recommendations "irresponsible" and detailed his conservative and...

NEW YORK, Sept. 28, 2012 /PRNewswire/ -- World-renowned Mount Sinai robotic prostate surgeon, Dr. David Samadi, devotes much of his time to prostate cancer education domestically and internationally. "My SMART robotic prostate removal surgery saves lives, but what men really want to know is how to prevent prostate cancer in the first place," shares Dr. Samadi. (Photo: http://photos.prnewswire.com/prnh/20120928/NY82860 ) More than 240,000 U.S. men are diagnosed with prostate...

NEW YORK, Sept. 12, 2012 /PRNewswire/ -- BRCA1/2 gene mutations, widely associated with breast and ovarian cancer risks in women, are, in principle, lethal to human embryos, according to new research conducted by three teams of researchers from the Center for Human Reproduction (CHR) in New York City, the Medical University Vienna in Vienna, Austria, and the Medical University Graz, Graz, Austria. BRCA1/2-positive embryos will only survive when also carrying a specific FMR1 gene...

TALLAHASSEE, Fla., Aug. 1, 2012 /PRNewswire/ -- The Large Urology Group Practice Association (LUGPA), representing more than 1,800 urologists, today applauded a newly released study confirming the impact of prostate-specific antigen (PSA) testing on the early detection of prostate cancer. The study, published online, and soon to be published in a print edition of Cancer, compared the incidence of advanced prostate cancer at initial diagnosis in 2008 to that seen before the...

Connie K. Ho for redOrbit.com - Your Universe Online While grenades have been mentioned in situations related to the military, they have never been mentioned in scientific research dealing with cancer. That is, until now. A new innovative drug by researchers at the Johns Hopkins Kimmel Cancer Center, in collaboration with Danish scientists, works like a “molecular grenade”; it can move through the bloodstream until activation by specific cancer proteins. The drug is made from a...

'Molecular grenade' now in clinical trials for advanced cancer Scientists at the Johns Hopkins Kimmel Cancer Center, working with Danish researchers, have developed a novel anticancer drug designed to travel -- undetected by normal cells -- through the bloodstream until activated by specific cancer proteins. The drug, made from a weedlike plant, has been shown to destroy cancers and their direct blood supplies, acting like a "molecular grenade," and sparing healthy blood vessels and...

BREA, Calif., June 25, 2012 /PRNewswire/ -- Beckman Coulter, Inc., the leader in prostate cancer diagnostics, announces Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the Prostate Health Index (phi), a simple, non-invasive blood test that is 2.5-times more specific in detecting prostate cancer[1] than PSA (prostate-specific antigen) in patients with PSA values in the 4-10 ng/mL range and is proven to reduce the number of prostate biopsies[2]. (Photo:...

BENTONVILLE, Ark., May 31, 2012 /PRNewswire/ -- June is Men's Health Month and with Father's Day just around the corner, Sam's Club Pharmacy locations invite you to show fathers and grandfathers how much you care by ensuring they are happy and healthy. Sam's Club observes Men's Health Month by offering free Men's Health Screenings on Saturday, June 9 from 11 a.m. to 3.p.m. Members and the public will receive a Prostate-Specific Antigen (PSA) test* to screen for accelerated...